Small Drug Makers Protest India’s New License-Centralizing Proposal
This article was originally published in PharmAsia News
Executive SummaryIndia's 5,000 small companies that make pharmaceuticals are challenging a government proposal to centralize the granting of manufacturing licenses, an authority now held by each state. The drug makers fear additional expenses and rules to get clearance. The head of India's Small Pharma Industry Confederation said proposed legislation is written in favor of multinational drug makers. Small firms cannot incur such huge costs, he said, asserting the responsibility should remain at the state level. (Click here for more
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.